Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

Cartalax (20mg Vial) Dosage Chart - Peptide Dosages

Cartalax (20mg Vial) Dosage Protocol Khavinson cartilage/connective-tissue peptide bioregulator (AED) — research-only; not approved, benefits unproven. Mix & measure Cartalax · 20 mg Pre-filled with this protocol’s recommended BAC water and documented starting

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

Cartalax (20mg Vial) Dosage Protocol

Khavinson cartilage/connective-tissue peptide bioregulator (AED) — research-only; not approved, benefits unproven.

Mix & measure Cartalax · 20 mg

Pre-filled with this protocol’s recommended BAC water and documented starting dose — edit any field to run your own numbers.

Reconstitution math only — not dosing advice. U-100 syringe: 100 units = 1 mL. Full reconstitution guide → · Advanced calculator →

Dosing & Reconstitution Guide

A single practical dilution with accurate once-daily dosing, step by step

Standard / Gradual Approach (3.0 mL = ~6.67 mg/mL)

Reconstitute: Add 3.0 mL bacteriostatic water to one 20 mg vial → final concentration ~6.67 mg/mL (6,667 mcg/mL).

Typical daily range: 2,000–5,000 mcg once daily, raised gradually over a 12-week course (high end for this class).

Easy measuring: At ~6.67 mg/mL, 1 unit ≈ 66.7 mcg on a U-100 syringe. The 3.0 mL dilution keeps every dose at 30 units or more for excellent measuring accuracy.

Storage: Lyophilized: store at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F) and do not freeze the mixed solution.

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

Related questions

01VK2735 — frequently asked questions

Wipe the stopper with an alcohol swab, then inject your bacteriostatic water slowly down the inside wall of the vial. Let it sit and gently swirl until dissolved — never shake. Store the mixed vial in the refrigerator and draw doses with an insulin syringe. Use the calculator above to turn any dose into syringe units. There is no single correct amount — more water simply spreads the same 10 mg of peptide across a larger volume, which makes small doses easier to measure accurately. 1 to 3 mL per vial is typical. Enter your chosen volume in the calculator above to see the resulting concentration and syringe units. On a U-100 insulin syringe, 100 units equal 1 mL, so 1 unit equals 0.01 mL. The calculator above converts your draw volume into these units automatically so you can measure without doing the math by hand. Keep the reconstituted vial refrigerated at roughly 2 to 8 degrees Celsius, away from light, and avoid freezing it. Reconstituted research peptides are generally used within a few weeks. Always follow the specific guidance supplied with your product. Divide the vial strength of 10 mg by the amount you use per injection. The calculator above reports this as "doses per vial" the moment you enter a dose. No. VK2735 is sold strictly for laboratory and research purposes and is not approved by the FDA or other regulators for human use. Everything on this page is research information, not medical advice — consult a licensed healthcare professional before any use.

Source: dosagepeptide.com ↗
02Ecnoglutide — frequently asked questions

Wipe the stopper with an alcohol swab, then inject your bacteriostatic water slowly down the inside wall of the vial. Let it sit and gently swirl until dissolved — never shake. Store the mixed vial in the refrigerator and draw doses with an insulin syringe. Use the calculator above to turn any dose into syringe units. There is no single correct amount — more water simply spreads the same 10 mg of peptide across a larger volume, which makes small doses easier to measure accurately. 1 to 3 mL per vial is typical. Enter your chosen volume in the calculator above to see the resulting concentration and syringe units. On a U-100 insulin syringe, 100 units equal 1 mL, so 1 unit equals 0.01 mL. The calculator above converts your draw volume into these units automatically so you can measure without doing the math by hand. Keep the reconstituted vial refrigerated at roughly 2 to 8 degrees Celsius, away from light, and avoid freezing it. Reconstituted research peptides are generally used within a few weeks. Always follow the specific guidance supplied with your product. Divide the vial strength of 10 mg by the amount you use per injection. The calculator above reports this as "doses per vial" the moment you enter a dose. No. Ecnoglutide is sold strictly for laboratory and research purposes and is not approved by the FDA or other regulators for human use. Everything on this page is research information, not medical advice — consult a licensed healthcare professional before any use.

Source: dosagepeptide.com ↗
03IGF-1 DES — frequently asked questions

Wipe the stopper with an alcohol swab, then inject your bacteriostatic water slowly down the inside wall of the vial. Let it sit and gently swirl until dissolved — never shake. Store the mixed vial in the refrigerator and draw doses with an insulin syringe. Use the calculator above to turn any dose into syringe units. There is no single correct amount — more water simply spreads the same 1 mg of peptide across a larger volume, which makes small doses easier to measure accurately. 1 to 3 mL per vial is typical. Enter your chosen volume in the calculator above to see the resulting concentration and syringe units. On a U-100 insulin syringe, 100 units equal 1 mL, so 1 unit equals 0.01 mL. The calculator above converts your draw volume into these units automatically so you can measure without doing the math by hand. Keep the reconstituted vial refrigerated at roughly 2 to 8 degrees Celsius, away from light, and avoid freezing it. Reconstituted research peptides are generally used within a few weeks. Always follow the specific guidance supplied with your product. Divide the vial strength of 1 mg by the amount you use per injection. The calculator above reports this as "doses per vial" the moment you enter a dose. No. IGF-1 DES is sold strictly for laboratory and research purposes and is not approved by the FDA or other regulators for human use. Everything on this page is research information, not medical advice — consult a licensed healthcare professional before any use.

Source: dosagepeptide.com ↗
04Humanin — frequently asked questions

Wipe the stopper with an alcohol swab, then inject your bacteriostatic water slowly down the inside wall of the vial. Let it sit and gently swirl until dissolved — never shake. Store the mixed vial in the refrigerator and draw doses with an insulin syringe. Use the calculator above to turn any dose into syringe units. There is no single correct amount — more water simply spreads the same 5 mg of peptide across a larger volume, which makes small doses easier to measure accurately. 1 to 3 mL per vial is typical. Enter your chosen volume in the calculator above to see the resulting concentration and syringe units. On a U-100 insulin syringe, 100 units equal 1 mL, so 1 unit equals 0.01 mL. The calculator above converts your draw volume into these units automatically so you can measure without doing the math by hand. Keep the reconstituted vial refrigerated at roughly 2 to 8 degrees Celsius, away from light, and avoid freezing it. Reconstituted research peptides are generally used within a few weeks. Always follow the specific guidance supplied with your product. Divide the vial strength of 5 mg by the amount you use per injection. The calculator above reports this as "doses per vial" the moment you enter a dose. No. Humanin is sold strictly for laboratory and research purposes and is not approved by the FDA or other regulators for human use. Everything on this page is research information, not medical advice — consult a licensed healthcare professional before any use.

Source: dosagepeptide.com ↗
05Pemvidutide — frequently asked questions

Wipe the stopper with an alcohol swab, then inject your bacteriostatic water slowly down the inside wall of the vial. Let it sit and gently swirl until dissolved — never shake. Store the mixed vial in the refrigerator and draw doses with an insulin syringe. Use the calculator above to turn any dose into syringe units. There is no single correct amount — more water simply spreads the same 5 mg of peptide across a larger volume, which makes small doses easier to measure accurately. 1 to 3 mL per vial is typical. Enter your chosen volume in the calculator above to see the resulting concentration and syringe units. On a U-100 insulin syringe, 100 units equal 1 mL, so 1 unit equals 0.01 mL. The calculator above converts your draw volume into these units automatically so you can measure without doing the math by hand. Keep the reconstituted vial refrigerated at roughly 2 to 8 degrees Celsius, away from light, and avoid freezing it. Reconstituted research peptides are generally used within a few weeks. Always follow the specific guidance supplied with your product. Divide the vial strength of 5 mg by the amount you use per injection. The calculator above reports this as "doses per vial" the moment you enter a dose. No. Pemvidutide is sold strictly for laboratory and research purposes and is not approved by the FDA or other regulators for human use. Everything on this page is research information, not medical advice — consult a licensed healthcare professional before any use.

Source: dosagepeptide.com ↗
Research context

Read sources and limitations before applying a claim.

2. Research use only

Any protocols, measurements, or instructions described are based on publicly available research data or general knowledge in the field. They are intended solely for research and educational reference, not for human or veterinary therapeutic use.

Source: dosagepeptide.com ↗

Research Models and Methodology: How This Question Is Studied

Because the clinical evidence is thin, most of what is known about NAD+ and Parkinson’s biology comes from experimental models, and understanding those models is essential to interpreting the claims made from them. The methodology spans several scales, each with characteristic strengths and blind spots. At the cellular level, researchers use dopaminergic cell lines and induced pluripotent stem cell (iPSC)-derived neurons, sometimes carrying Parkinson’s-associated mutations such as PINK1, PRKN, LRRK2, or GBA. These systems allow precise measurement of NAD+/NADH ratios, mitochondrial membrane potential, oxygen-consumption rate (via Seahorse-type respirometry), ATP output, mitophagy flux, and alpha-synuclein aggregation, and they permit clean genetic and pharmacological manipulation. Their limitation is context: a neuron in a dish lacks the aging, the vasculature, the glial partners, and the decades-long timescale of human disease. A compound that restores NAD+ and rescues mitochondrial function in a two-week culture experiment has cleared a low bar relative to a human brain.5,6 At the organismal level, the workhorses are toxin and genetic models. Toxin models use complex I inhibitors, chiefly MPTP in mice and non-human primates and rotenone in rats, to acutely damage dopaminergic neurons; these reproduce the bioenergetic lesion and motor deficits but not the slow, spreading, age-dependent synucleinopathy of human disease. Genetic models overexpress human alpha-synuclein or knock out mitophagy genes, capturing aspects of aggregation and quality-control failure but often with incomplete nigral cell loss. Invertebrate models in Drosophila and C. elegans allow rapid, high-throughput testing of NAD+ manipulation on survival and locomotion. Across these systems, NAD+ boosting has repeatedly improved outcomes, which is encouraging but must be weighted by the well-documented poor translation of Parkinson’s models to human neuroprotection.1 The methodological centerpiece of the human work is target engagement measurement. It is not enough to give an oral precursor and hope; investigators need to know whether brain NAD+ actually changed. The NADPARK program used phosphorus-31 magnetic resonance spectroscopy, a non-invasive technique that detects NAD+ and NADH resonances in living brain tissue, to demonstrate that oral NR raised cerebral NAD+ in a subset of participants.1 This is a genuine methodological advance, because it converts a plausibility argument (“the precursor should reach the brain”) into a measurement, and it also revealed the important reality of responders and non-responders: not everyone who took NR showed a rise in brain NAD+, which has major implications for trial design and for interpreting any downstream clinical effect. Complementary readouts included FDG-PET for cerebral glucose metabolism, cerebrospinal fluid metabolomics, and blood and skeletal-muscle transcriptomics to trace the systemic response.1 Clinical outcome measurement introduces its own methodology. The standard instrument is the Movement Disorder Society Unified Parkinson’s Disease Rating Scale (MDS-UPDRS), a multi-part rating of motor and non-motor function. It is the accepted primary-endpoint measure in NOPARK, but it has meaningful test-retest variability, is sensitive to the timing of symptomatic dopaminergic medication, and depends partly on examiner judgment. This is precisely why the NR-SAFE authors flagged levodopa-timing as a possible confounder of their UPDRS signal, and why short trials are ill-suited to detecting the slow separation of progression curves that disease modification would produce.2 A well-designed efficacy trial therefore needs adequate size, a long enough duration for progression to manifest, blinding, standardized assessment conditions, and ideally pre-specified biomarker sub-analyses to separate responders from non-responders. The gap between the elegant mechanistic experiments and the demanding requirements of a convincing clinical trial is exactly where enthusiasm most often outruns evidence.

Source: dosagepeptide.com ↗
Practical and safety references

These excerpts are educational, not personalised medical instructions.

How-to reference

How to Read the 3% to 10% SNAP-8 Range

The ingredient developer supplied SNAP-8 as a preserved aqueous blend containing approximately 0.05% acetyl octapeptide-3. Adding 3% to 10% of that solution gives 0.0015% to 0.005% actual peptide in the final product[6]. A raw 10 mg vial and a preserved commercial premix are not operationally interchangeable. 3% 0.05% 0.0015% 6% 0.0030% 10% 0.0050%

Source: peptidedosages.com ↗
Dosage reference

Where this fits in the dosing math

This converter only changes units — it does not tell you what dose to use, and it is not a substitute for the compound-specific information on each protocol page. Its job is to hand the next step a clean number. Once your dose is expressed in milligrams, the peptide dosage calculator and the reconstitution calculator turn that milligram figure, your vial strength, and your bacteriostatic water into the exact volume and syringe units to draw. For the full reconstitution walk-through — water, sterility, storage and syringes — see the peptide reconstitution guide, and if a term here is unfamiliar, the peptide glossary defines it. Keep the two jobs separate and the arithmetic stays trustworthy: this page converts units with certainty, and the compound-specific material handles what those units should be. Everything here is for research and educational use only and is not medical advice.

Source: dosagepeptide.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →